PROTHENA CORP PUBLIC LTD CO
About PROTHENA CORP PUBLIC LTD CO
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $9.7M
- Net income
- -$244.1M
- Total assets
- $326.8M
- Market cap
- $460.2M
- Operating margin
- -2216.4%
- Net margin
- -2520.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.7M
- Operating expenses
- $224.3M
- Operating income
- -$214.6M
- Income tax
- $43.3M
- Net income
- -$244.1M
- EPS (basic)
- $-4.53
- EPS (diluted)
- $-4.53
Balance sheet
- Total assets
- $326.8M
- Current assets
- $315.2M
- Total liabilities
- $46.3M
- Current liabilities
- $40.8M
- Shareholders’ equity
- $280.5M
Cash flow
- Operating cash flow
- -$163.6M
- Investing cash flow
- -$138.0K
- Financing cash flow
- -$139.0K
- Net cash flow
- -$163.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $460.2M
- EPS (diluted)
- $-4.53
- Shares outstanding
- 53.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 18, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $244.1M in FY2025.
- Revenue declined 95% from FY2021 to FY2025.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PROTHENA CORP PUBLIC LTD CO.
Write a review
News about PROTHENA CORP PUBLIC LTD CO
News & sentiment via Polygon.io
